L. Garrison, . Jr, P. Neumann, P. Erickson, D. Marshall et al., Using Real-World Data for Coverage and Payment Decisions: The ISPOR Real-World Data Task Force Report, Value in Health, vol.10, issue.5, pp.326-361, 2007.
DOI : 10.1111/j.1524-4733.2007.00186.x

D. Zackova, H. Klamova, L. Dusek, J. Muzik, K. Polakova et al., Imatinib as the first-line treatment of patients with chronic myeloid leukemia diagnosed in the chronic phase: Can we compare real life data to the results from clinical trials?, American Journal of Hematology, vol.86, issue.3, pp.318-339, 2011.
DOI : 10.1002/ajh.21942

M. Argyropulo-palmer, A. Jenkins, D. Theti, J. Larkin, and D. Montgomery, Sunitinib in Metastatic Renal Cell Carcinoma: A Systematic Review of UK Real World Data, Frontiers in Oncology, vol.335, issue.15 Suppl, p.195, 2015.
DOI : 10.1136/bmj.39335.541782.AD

M. Harrison, D. George, M. Walker, C. Chen, B. Korytowsky et al., ???Real World??? Treatment of Metastatic Renal Cell Carcinoma in a Joint Community-Academic Cohort: Progression-Free Survival Over Three Lines of Therapy, Clinical Genitourinary Cancer, vol.11, issue.4, pp.441-50, 2013.
DOI : 10.1016/j.clgc.2013.05.002

T. Choueiri, M. Duh, J. Clement, A. Brick, M. Rogers et al., Angiogenesis inhibitor therapies for metastatic renal cell carcinoma: effectiveness, safety and treatment patterns in clinical practice-based on medical chart review, BJU International, vol.99, issue.9, pp.1247-54, 2010.
DOI : 10.1111/j.1464-410X.2009.08972.x

L. Albiges, T. Choueiri, B. Escudier, M. Galsky, D. George et al., A Systematic Review of Sequencing and Combinations of Systemic Therapy in Metastatic Renal Cancer, European Urology, vol.67, issue.1, pp.100-110, 2015.
DOI : 10.1016/j.eururo.2014.04.006

P. Marchetti, N. Maass, J. Gligorov, K. Berger, F. Macdougall et al., Patient database analysis of fulvestrant 500??mg in the treatment of metastatic breast cancer: A European perspective, The Breast, vol.32, pp.247-55, 2017.
DOI : 10.1016/j.breast.2016.12.002
URL : https://hal.archives-ouvertes.fr/hal-01421146

L. Benjamin, R. Maroun, F. Maurel, I. Bardoulat, and C. Ricarte, Patterns of use of oral anticancer treatments in France: a Retrospective Analysis of Cancer Treatments given ORally from 2004 to 2012 (Re-ACTOR study), Current Medical Research and Opinion, vol.31, issue.2, pp.323-355, 2015.
DOI : 10.1185/03007995.2014.986324

R. Maroun, F. Maunoury, L. Benjamin, G. Nachbaur, and I. Durand-zaleski, In-hospital economic burden of metastatic renal cell carcinoma in France in the era of targeted therapies: analysis of the French National Hospital Database from, PLoS One, vol.11, issue.9, p.162864, 2008.

P. Cairns, Renal cell carcinoma, Cancer Biomarkers, vol.9, issue.1-6, pp.461-73, 2010.
DOI : 10.3233/CBM-2011-0176

D. Geynisman, J. Hu, L. Liu, T. Shih, and Y. , Treatment Patterns and Costs for Metastatic Renal Cell Carcinoma Patients With Private Insurance in??the United States, Clinical Genitourinary Cancer, vol.13, issue.2, pp.93-100, 2015.
DOI : 10.1016/j.clgc.2014.08.013

H. Abe and T. Kamai, Recent advances in the treatment of metastatic renal cell carcinoma, International Journal of Urology, vol.25, issue.Suppl 1, pp.944-55, 2013.
DOI : 10.1200/JCO.2007.10.8613

B. Ljungberg, K. Bensalah, A. Bex, S. Canfield, S. Dabestani et al., Renal Cell Carcinoma Guideline, European Urology, vol.51, issue.6
DOI : 10.1016/j.eururo.2007.03.035
URL : https://hal.archives-ouvertes.fr/inserm-00405692

E. Jonasch, J. Signorovitch, P. Lin, Z. Liu, K. Culver et al., Treatment patterns in metastatic renal cell carcinoma: a retrospective review of medical records from US community oncology practices, Current Medical Research and Opinion, vol.30, issue.10, pp.2041-50, 2014.
DOI : 10.1185/03007995.2014.938730

D. Day, Y. Kanjanapan, E. Kwan, D. Yip, N. Lawrentschuk et al., Patterns of care for metastatic renal cell carcinoma in Australia, BJU International, vol.115, issue.Suppl. 4, pp.36-41, 2015.
DOI : 10.1002/cncr.24051

J. Wagstaff, R. Jones, R. Hawkins, E. Porfiri, L. Pickering et al., Treatment patterns and clinical outcomes in patients with renal cell carcinoma in the UK: insights from the RECCORD registry, Annals of Oncology, vol.16, issue.1, pp.159-65, 2016.
DOI : 10.1016/j.urolonc.2010.07.015

I. Schnadig, T. Hutson, H. Chung, R. Dhanda, M. Halm et al., Dosing Patterns, Toxicity, and Outcomes in Patients Treated With First-Line Sunitinib for Advanced Renal Cell Carcinoma in Community-Based Practices, Clinical Genitourinary Cancer, vol.12, issue.6, pp.413-434, 2014.
DOI : 10.1016/j.clgc.2014.06.015

R. Motzer, T. Hutson, P. Tomczak, M. Michaelson, R. Bukowski et al., Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma, Journal of Clinical Oncology, vol.27, issue.22, pp.3584-90, 2009.
DOI : 10.1200/JCO.2008.20.1293

B. Escudier, T. Eisen, W. Stadler, C. Szczylik, S. Oudard et al., Sorafenib in Advanced Clear-Cell Renal-Cell Carcinoma, New England Journal of Medicine, vol.356, issue.2, pp.125-159, 2007.
DOI : 10.1056/NEJMoa060655

M. Gore, C. Szczylik, C. Porta, S. Bracarda, G. Bjarnason et al., Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial, The Lancet Oncology, vol.10, issue.8, pp.757-63, 2009.
DOI : 10.1016/S1470-2045(09)70162-7

R. Motzer, T. Hutson, D. Cella, J. Reeves, R. Hawkins et al., Pazopanib versus Sunitinib in Metastatic Renal-Cell Carcinoma, New England Journal of Medicine, vol.369, issue.8, pp.722-753, 2013.
DOI : 10.1056/NEJMoa1303989

R. Motzer, T. Hutson, P. Tomczak, M. Michaelson, R. Bukowski et al., Sunitinib versus Interferon Alfa in Metastatic Renal-Cell Carcinoma, New England Journal of Medicine, vol.356, issue.2, pp.115-139, 2007.
DOI : 10.1056/NEJMoa065044